Trypanosomiasis
Drug research and approvals for trypanosomiasis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 20, 2026, 4 studies of trypanosomiasis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 3 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 4
- Trials authorized in Canada: 0
- FDA orphan approvals: 3
- EU medicines: 0
- Stop Transmission of Gambiense Human African TrypanosomiasisNCT07789743 · Phase 3 · Institute of Tropical Medicine, Belgium · starts Mar 15, 2024
- A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.NCT06632600 · Phase 2 · Novartis Pharmaceuticals · starts Apr 28, 2025
- Cardiac Contractility Modulation in Chagas Heart DiseaseNCT05519046 · Not applicable · InCor Heart Institute · starts May 25, 2022
- Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas DiseaseNCT04897516 · Phase 3 · Laboratorio Elea Phoenix S.A. · starts Jul 28, 2021
Approved 8
- NifurtimoxDNA inhibitor
- FexinidazoleCytotoxic
- PentamidineDNA inhibitor
- Benznidazole
- Miltefosine
- Acetarsone
- NitrofurazoneDNA inhibitor
- Stibogluconic acid
Phase 3 4
- EflornithineOrnithine decarboxylase inhibitor
- Melarsoprol
- SuraminAcidic fibroblast growth factor inhibitor
- Meglumine antimonate
Phase 2 1
- PafuramidineKinetoplast DNA inhibitor
Phase 1 or earlier 3
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- DextromethorphanSigma opioid receptor agonist
- AcoziboroleCleavage and polyadenylation specificity factor subunit inhibitor
How its trials ended
32 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 14 whose ending is known, 57% met their primary endpoint, 7% missed it and 36% stopped early.
- Completed, result not reported1444%
- Met its primary endpoint825%
- Stopped: other or unclear39%
- Ongoing26%
- Status unknown26%
- Missed its primary endpoint13%
- Stopped: lack of efficacy13%
- Stopped: enrollment or feasibility13%
| Jul 16, 2021 | FexinidazoleTreatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to… | Sanofi US Services Inc., A SANOFI COMPANY | Approved |
| Aug 6, 2020 | LampitLAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas… | Bayer HealthCare Pharmaceuticals, Inc. | Approved |
| Aug 29, 2017 | BenznidazoleTreatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age. | Chemo Research, S.L. | Approved |
| Jan 25, 2021 | SuraminTreatment of human African trypanosomiasis | PaxMedica, Inc. | Designated |
| Aug 31, 2007 | Pafuramidine maleateTreatment of human African trypanosomiasis (sleeping sickness) | Immtech Pharmaceuticals, Inc. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA